Search results for: 'ride of artificial intelligence in drug discovery and development'

Artificial Intelligence (AI) has emerged to be one of the most essential technologies to develop machine intelligence. The technology has advanced significantly over the ages to empower applications and machines to learn from its own experiences and perform autonomously. Technology evolution in the AI space is continuously driving the development o...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....

Enterprise digitalization and surging adoption of IoT applications have led to voluminous amounts of complex structured and unstructured data that require processing to draw meaningful insights. A Frost & Sullivan voice of customer (VOC) global survey on artificial intelligence (AI) finds that 43% of enterprises list data-centricity as a key busine...

For a long time, drug discovery followed the same path and used conventional analysis methods for proposed targets. Today, changes in technology and the ability to study omics are transforming drug development. Personalized therapy is on the rise and promises to be more effective and efficient in addressing challenges. With growing interest in ...

This Frost & Sullivan research examines the growing need for artificial intelligence (AI) services to help businesses meet key goals and objectives, as well as the strategic position of public cloud service providers to develop and launch successful AI capabilities for customers. The report discusses the importance of public cloud providers in the ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides actionable insights across new developments in prebiotics, immunology, oncology, cell and gene therapies, antibody therapies, and precision medicine approaches. The TOE also encompasses technology advances across the use of AI and ML in drug discovery a...

The SynBio field has evolved well over the past two decades, with significant technology disruptions leading to new opportunities and remarkable growth potential. Advances in SynBio technologies have transformed drug discovery and therapeutics development, accelerating the identification of novel drug targets and high-throughput compound screening ...

The discovery of new drug targets for diseases with unmet medical needs has long been hindered by the complexity of processing and interpreting massive volumes of biological data. The increasing volume and veracity of clinical and research data compels the use of enabling tools and technologies, such as cloud computing, AI, machine learning, natura...

The conventional drug discovery and diagnostics technologies are unable to cope up with the current disease management practices. To this end, researchers have explored possibilities beyond life sciences. Specifically, they have figured out that the use of engineering principles to biological systems can revolutionize the drug discovery and diagnos...